Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The ...

2-Year U.S. Treasury Note Continuous Contract $104.395-0.035-0.03% 5-Year U.S. Treasury Note Continuous Contract $109.227-0.195-0.18% 10-Year U.S. Treasury Note Continuous Contract $112.297-0.344-0.31 ...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.

Challenge yourself every day with a free mini version of the classic crossword puzzle. Can you solve The Mini in minutes — or seconds? Play a new puzzle every day or browse the archive. Jump in to ...